Sulfadoxine-pyrimethamine
| Product vision |
- Intermittent preventive treatment (TPP-1) during pregnancy (IPTp)
|
| Dosing |
- 1500mg sulfadoxine - 75 mg pyrimethamine (SP; dosed via three tablets), to be given at the beginning of the 2nd trimester of pregnancy at least one month apart until delivery
|
| Efficacy |
- WHO affirmed the effectiveness of IPTp using SP (IPTp-SP), including in areas with SP resistance
- Estimates indicate that a full course of IPTp-SP decreases the incidence of low birth weight babies by 29%, severe maternal anaemia by 38%, and neonatal mortality by 31%. It is also one of the few health interventions showing reductions in neonatal mortality
|
| Key features |
- Adapted SP packaging to ensure correct use and to improve perception and uptake
|
| Challenges |
- Delivery of IPTp requires a functioning antenatal care platform and access to quality-assured SP
- Improving quality perceptions about SP and expanding access through community health worker channels can increase IPTp coverage
|
| Status |
- Bioequivalence study in preparation
|
| Next milestone |
- Bioequivalence study start
|
| MMV Project Director |
|